(FDA) on Friday granted its first emergency use authorization (EUA) for a blood purification system to treat patients at risk for respiratory failure due to coronavirus disease (COVID-19). The EUA was granted to Terumo BCT Inc. and Marker Therapeutics authorizing the use of their Spectra Optia Apheresis System and Depuro D2000 Adsorption Cartridge devices to filter cytokines and other inflammatory proteins from patients’ blood. ...